Clinical trial · no report yet · Phase 3
NCT05561387
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- NCT05561387 ↗
- Recruiting
- SWOG Cancer Research Network
- 3 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Plasma Cell Myeloma
- Interventions
- Bortezomib; Daratumumab and Hyaluronidase-fihj; Dexamethasone; Lenalidomide; Quality-of-Life Assessment; Questionnaire Administration
- Arms
- Arm I (VRd-Lite) · Active comparator
- Arm II (DRd-R) · Experimental
- Arm III (DRd-DR): · Experimental
- Enrollment
- 510 (estimated)
- Primary outcomes
- Progression free survival (PFS) of Arm 1 versus (vs.) Arm 2
- Overall survival (OS) of Arm 1 vs. Arm 3
- Sponsor
- SWOG Cancer Research Network with National Cancer Institute (NCI)
- Start
- Oct 12, 2023
- Primary completion
- May 30, 2031 (estimated)
- Results posted
- No
- Registry record
- NCT05561387 · updated Jun 10, 2026